What's Going On With Capricor Therapeutics Stock Tuesday?
Portfolio Pulse from Dylan Berman
Capricor Therapeutics (NASDAQ: CAPR) shares are trading higher after the company reported progress on its CAP-1002 treatment for Duchenne Muscular Dystrophy. The FDA has agreed to a pre-Biologics License Application meeting, allowing a rolling submission starting in Q3 2024.
June 11, 2024 | 7:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics shares are up 3.23% after the FDA agreed to a pre-BLA meeting for CAP-1002, a potential treatment for Duchenne Muscular Dystrophy. The rolling submission for the BLA will start in Q3 2024.
The FDA's agreement to a pre-BLA meeting is a significant regulatory milestone for Capricor Therapeutics. This progress increases investor confidence in the potential approval and commercialization of CAP-1002, leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100